Discrimination suit against Merck expanded; Rugby players shill for Menarini premature ejaculation drug;

@FiercePharma: Big Pharma accused of hatching 'satanic plot' in South Africa. More | Follow @FiercePharma

@TracyStaton: Trending at FiercePharma: Novartis may finally face generic competition for Diovan. Yesterday's story | Follow @TracyStaton

@EricPFierce: FDA investigator assigned to Europol to fight fakes being hawked online by drug rings. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Look for Teva's new chief to move fast on dealmaking, CFO says. Story | Follow @CarlyHFierce

> India's drug regulator is considering changes for labeling on drug packages to make sure consumers can tell what company made the medication and who is marketing it. Story

> Four more women have joined a gender discrimination lawsuit filed last year against Merck & Co ($MRK), in which the drugmaker is alleged to have suggested to female sales reps that having babies was bad for business. Release

> Aegerion Pharmaceuticals ($AEGR), which is having its marketing probed by the Justice Department, was hit by a shareholder suit accusing it of misleading shareholders about off-label marketing of its cholesterol drug Juxtapid. Story (sub req.) 

> A new study shows that patients getting multiple medicines for multiple conditions are not more likely to be readmitted to the hospital, as previously believed. Story

Medical Device News

@FierceMedDev: Boston Scientific won't begin its U.S. hypertension study until it reviews Medtronic's setback. More | Follow @FierceMedDev

@MarkHFierce: Google is developing a contact lens that monitors glucose levels. Partners needed to bring the product to market. Story | Follow @MarkHFierce

@MichaelGFierce: Study: Carotid stents, regardless of origin, are similarly effective at preventing stroke, death. Item | Follow @MichaelGFierce

@EmilyWFierce: Flu season predictions from scientists at Columbia could help you stay out of bed. Article | Follow @EmilyWFierce

@GalenMoore: Here's who was in the room when a team from Google X met with FDA officials last month. | Follow @GalenMoore

> A (now) broken record: Med tech VC funding dropped again in 2013. News

> BioMérieux closes BioFire Diagnostics deal for $450M plus debt. Story

Biotech News

@FierceBiotech: Auspex's $76M IPO pitch tests the limits of biotech's window. Story | Follow @FierceBiotech

@JohnCFierce: ICYMI: Roche 's dealmakers at pRED will continue their global shopping spree in 2014. Piece | Follow @JohnCFierce

@DamianFierce: Welcome back, Ariad: Iclusig returns after a cold winter. More | Follow @DamianFierce

@EmilyMFierce: Experimental microparticle therapy could treat inflammatory conditions, from effects of heart attack to diabetes. Article | Follow @EmilyMFierce

> Prosensa heralds new hope for once-failed muscular dystrophy drug. More

> Shire takes an L on Dermagraft, unloads it to Organogenesis. Story

> ArQule rides high on good news for its never-say-die cancer drug. News

And Finally.... Italian drugmaker Menarini has signed up international rugby players Danny Care, Sean Maitland and Dan Biggar in support of its new advertising campaign, "Firing Too Quickly" in support of its treatment for premature ejaculation. Story

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.